1. Home
  2. EYPT vs EVO Comparison

EYPT vs EVO Comparison

Compare EYPT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYPT
  • EVO
  • Stock Information
  • Founded
  • EYPT 1987
  • EVO 1993
  • Country
  • EYPT United States
  • EVO Germany
  • Employees
  • EYPT N/A
  • EVO N/A
  • Industry
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • EVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • EYPT Industrials
  • EVO Health Care
  • Exchange
  • EYPT Nasdaq
  • EVO Nasdaq
  • Market Cap
  • EYPT 967.4M
  • EVO 1.1B
  • IPO Year
  • EYPT 2005
  • EVO 2021
  • Fundamental
  • Price
  • EYPT $14.50
  • EVO $3.18
  • Analyst Decision
  • EYPT Strong Buy
  • EVO Strong Buy
  • Analyst Count
  • EYPT 5
  • EVO 1
  • Target Price
  • EYPT $29.60
  • EVO $7.00
  • AVG Volume (30 Days)
  • EYPT 1.4M
  • EVO 79.1K
  • Earning Date
  • EYPT 11-05-2025
  • EVO 11-05-2025
  • Dividend Yield
  • EYPT N/A
  • EVO N/A
  • EPS Growth
  • EYPT N/A
  • EVO N/A
  • EPS
  • EYPT N/A
  • EVO N/A
  • Revenue
  • EYPT $42,339,000.00
  • EVO $887,396,457.00
  • Revenue This Year
  • EYPT N/A
  • EVO N/A
  • Revenue Next Year
  • EYPT N/A
  • EVO $10.78
  • P/E Ratio
  • EYPT N/A
  • EVO N/A
  • Revenue Growth
  • EYPT N/A
  • EVO N/A
  • 52 Week Low
  • EYPT $3.91
  • EVO $2.84
  • 52 Week High
  • EYPT $14.91
  • EVO $5.10
  • Technical
  • Relative Strength Index (RSI)
  • EYPT 65.45
  • EVO 43.43
  • Support Level
  • EYPT $13.43
  • EVO $2.89
  • Resistance Level
  • EYPT $14.67
  • EVO $3.24
  • Average True Range (ATR)
  • EYPT 0.91
  • EVO 0.09
  • MACD
  • EYPT 0.32
  • EVO -0.00
  • Stochastic Oscillator
  • EYPT 99.54
  • EVO 62.50

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: